Cargando…

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

BACKGROUND: Lymphangioleiomyomatosis is a rare disease caused by unregulated activation of mammalian target of rapamycin (mTOR) signalling pathway. Sirolimus showed efficacy in a phase 3 trial of patients with lymphangioleiomyomatosis, but the optimal dose remains unclear. METHODS: We investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Hee-Young, Hwang, Jung Jin, Kim, Dong Soon, Song, Jin Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236936/ https://www.ncbi.nlm.nih.gov/pubmed/30428897 http://dx.doi.org/10.1186/s13023-018-0946-8

Ejemplares similares

Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
por: Hu, Siqi, et al.
Publicado: (2019)

Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis
por: Steagall, Wendy K., et al.
Publicado: (2023)

Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis
por: Aghaeimeybodi, Fatemeh, et al.
Publicado: (2019)

Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series
por: Zhou, Li, et al.
Publicado: (2018)

Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2022)

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
por: Zhan, Yongzhong, et al.
Publicado: (2018)

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
por: Neurohr, Claus, et al.
Publicado: (2011)

Sirolimus in lymphangioleiomyomatosis: A case in point for research in ‘orphan’ diseases
por: Koul, Parvaiz A, et al.
Publicado: (2019)

Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
por: Namba, Masashi, et al.
Publicado: (2017)

The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis
por: Wang, Qi, et al.
Publicado: (2020)

Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus
por: Sakaue, Takahiko, et al.
Publicado: (2018)

Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier
por: Sonobe, Shoko, et al.
Publicado: (2018)

Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus
por: Ko, Yuki, et al.
Publicado: (2020)

Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report
por: Verma, Ajay Kumar, et al.
Publicado: (2018)

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015)

Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis
por: Huang, Yen-Lin, et al.
Publicado: (2021)

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis
por: Sakurai, Teiko, et al.
Publicado: (2021)

Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort
por: Gopalakrishnan, Vissagan, et al.
Publicado: (2018)

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
por: Parker, Victoria E. R., et al.
Publicado: (2018)

Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
por: Revilla-López, Eva, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study
por: Cheng, Chongsheng, et al.
Publicado: (2022)

Comparison of Early and Late Conversion of Sirolimus in Experimental Model of Chronic Cyclosporine Nephropathy
por: Kim, Jin Young, et al.
Publicado: (2012)

Low-dose sirolimus in retroperitoneal lymphangioleiomyomas
por: Ussavarungsi, Kamonpun, et al.
Publicado: (2019)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

A Nationwide Survey of Lymphangioleiomyomatosis in Korea: Recent Increase in Newly Diagnosed Patients
por: Park, Hye Yun, et al.
Publicado: (2010)

Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches
por: Kim, Minji, et al.
Publicado: (2023)

Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice
por: Youn, Young Jin, et al.
Publicado: (2019)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

Pulmonary lymphangioleiomyomatosis in a male.
por: Kang, H. W., et al.
Publicado: (1991)

Safety and efficacy of Rapamune® (Sirolimus) in kidney transplant recipients: results of a prospective post-marketing surveillance study in Korea
por: Jeon, Hee Jung, et al.
Publicado: (2018)

Long-Term Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Stents in Patients With Acute Myocardial Infarction: Four-Year Observational Study
por: Min, Gye-Sik, et al.
Publicado: (2012)

Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus
por: Harbers, Veroniek E. M., et al.
Publicado: (2021)

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
por: Eriksson, Per, et al.
Publicado: (2019)

Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment
por: Song, Xixi, et al.
Publicado: (2020)

Treatment of lymphangioleiomyomatosis and Camões
por: Rufino, Rogério
Publicado: (2015)

Methylprednisolone in the treatment of lymphangioleiomyomatosis
por: Dale, Ventour, et al.
Publicado: (2022)

Chylothorax, in the Spotlight of Lymphangioleiomyomatosis
por: Gámez-Baeza, Pablo, et al.
Publicado: (2022)

A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients
por: Zheng, Xiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4tcvko91qdqevsq5nlk0jppkh1